Intellia Therapeutics, Inc.

NTLA ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $155.5M $189.2M $226.7M $523.5M $123.4M $160.0M $57.2M $58.9M
Accounts Receivable $9.5M $8.5M $36.5M $3.8M $2.0M $2.1M $4.6M $7.5M
Inventory — — — — — — — —
Total Current Assets $527.7M $639.9M $998.3M $1.22B $769.3M $616.5M $289.5M $325.0M
Property, Plant & Equipment $17.7M $27.4M $32.8M $27.9M $21.0M $15.9M $18.0M $17.1M
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) — — — — — — — —
Total Assets $842.1M $1.19B $1.30B $1.52B $1.29B $676.3M $334.3M $347.3M
Liabilities
Accounts Payable $20.3M $14.6M $7.5M $5.2M $9.7M $10.5M $3.9M $2.7M
Total Current Liabilities $103.9M $110.9M $115.2M $126.6M $125.8M $64.3M $35.6M $40.6M
Long-Term Debt — — — — — — — —
Total Liabilities $170.7M $319.1M $250.8M $284.5M $254.2M $149.3M $64.4M $69.4M
Stockholders' Equity
Retained Earnings $-2.59B $-2.18B $-1.66B $-1.18B $-703.0M $-435.1M $-300.9M $-201.0M
Total Stockholders' Equity $671.4M $872.0M $1.05B $1.24B $1.04B $527.1M $269.9M $277.9M
← Newer Page 1 of 2 Older →